S&P 500   3,894.87 (-0.18%)
DOW   31,558.08 (+0.07%)
QQQ   321.56 (-0.63%)
AAPL   126.39 (-1.10%)
MSFT   235.00 (-0.82%)
FB   264.95 (+0.02%)
GOOGL   2,077.65 (+0.39%)
TSLA   706.13 (-1.71%)
AMZN   3,139.10 (-0.22%)
NVDA   545.61 (-1.46%)
BABA   238.25 (-1.42%)
CGC   35.72 (+2.85%)
GE   13.06 (-0.38%)
MU   92.34 (-2.55%)
NIO   44.17 (-11.23%)
AMD   85.79 (-0.69%)
T   28.35 (+0.93%)
F   12.53 (+4.59%)
ACB   11.43 (+3.53%)
DIS   194.94 (-0.02%)
BA   224.00 (-0.17%)
NFLX   551.71 (+0.19%)
BAC   35.63 (-0.45%)
S&P 500   3,894.87 (-0.18%)
DOW   31,558.08 (+0.07%)
QQQ   321.56 (-0.63%)
AAPL   126.39 (-1.10%)
MSFT   235.00 (-0.82%)
FB   264.95 (+0.02%)
GOOGL   2,077.65 (+0.39%)
TSLA   706.13 (-1.71%)
AMZN   3,139.10 (-0.22%)
NVDA   545.61 (-1.46%)
BABA   238.25 (-1.42%)
CGC   35.72 (+2.85%)
GE   13.06 (-0.38%)
MU   92.34 (-2.55%)
NIO   44.17 (-11.23%)
AMD   85.79 (-0.69%)
T   28.35 (+0.93%)
F   12.53 (+4.59%)
ACB   11.43 (+3.53%)
DIS   194.94 (-0.02%)
BA   224.00 (-0.17%)
NFLX   551.71 (+0.19%)
BAC   35.63 (-0.45%)
S&P 500   3,894.87 (-0.18%)
DOW   31,558.08 (+0.07%)
QQQ   321.56 (-0.63%)
AAPL   126.39 (-1.10%)
MSFT   235.00 (-0.82%)
FB   264.95 (+0.02%)
GOOGL   2,077.65 (+0.39%)
TSLA   706.13 (-1.71%)
AMZN   3,139.10 (-0.22%)
NVDA   545.61 (-1.46%)
BABA   238.25 (-1.42%)
CGC   35.72 (+2.85%)
GE   13.06 (-0.38%)
MU   92.34 (-2.55%)
NIO   44.17 (-11.23%)
AMD   85.79 (-0.69%)
T   28.35 (+0.93%)
F   12.53 (+4.59%)
ACB   11.43 (+3.53%)
DIS   194.94 (-0.02%)
BA   224.00 (-0.17%)
NFLX   551.71 (+0.19%)
BAC   35.63 (-0.45%)
S&P 500   3,894.87 (-0.18%)
DOW   31,558.08 (+0.07%)
QQQ   321.56 (-0.63%)
AAPL   126.39 (-1.10%)
MSFT   235.00 (-0.82%)
FB   264.95 (+0.02%)
GOOGL   2,077.65 (+0.39%)
TSLA   706.13 (-1.71%)
AMZN   3,139.10 (-0.22%)
NVDA   545.61 (-1.46%)
BABA   238.25 (-1.42%)
CGC   35.72 (+2.85%)
GE   13.06 (-0.38%)
MU   92.34 (-2.55%)
NIO   44.17 (-11.23%)
AMD   85.79 (-0.69%)
T   28.35 (+0.93%)
F   12.53 (+4.59%)
ACB   11.43 (+3.53%)
DIS   194.94 (-0.02%)
BA   224.00 (-0.17%)
NFLX   551.71 (+0.19%)
BAC   35.63 (-0.45%)
Log in
NASDAQ:AKBA

Akebia Therapeutics Stock Forecast, Price & News

$3.49
+0.12 (+3.56 %)
(As of 03/2/2021 12:46 PM ET)
Add
Compare
Today's Range
$3.38
Now: $3.49
$3.49
50-Day Range
$3.04
MA: $3.81
$5.06
52-Week Range
$2.09
Now: $3.49
$13.71
Volume105,203 shs
Average Volume7.61 million shs
Market Capitalization$504.44 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKBA
CUSIPN/A
Phone617-871-2098
Employees358
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$335 million
Book Value$3.32 per share

Profitability

Net Income$-279,660,000.00
Net Margins-126.86%

Miscellaneous

Market Cap$504.44 million
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

281st out of 1,968 stocks

Pharmaceutical Preparations Industry

138th out of 772 stocks

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$3.49
+0.12 (+3.56 %)
(As of 03/2/2021 12:46 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

Is Akebia Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Akebia Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKBA, but not buy additional shares or sell existing shares.
View analyst ratings for Akebia Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Akebia Therapeutics?

Wall Street analysts have given Akebia Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Akebia Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Akebia Therapeutics
.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings data on Wednesday, February, 24th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.20. Akebia Therapeutics had a negative net margin of 126.86% and a negative trailing twelve-month return on equity of 68.51%.
View Akebia Therapeutics' earnings history
.

How has Akebia Therapeutics' stock been impacted by Coronavirus?

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AKBA stock has decreased by 50.6% and is now trading at $3.43.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AKBA?

7 Wall Street analysts have issued 12-month price targets for Akebia Therapeutics' stock. Their forecasts range from $3.00 to $18.00. On average, they expect Akebia Therapeutics' stock price to reach $10.29 in the next twelve months. This suggests a possible upside of 199.9% from the stock's current price.
View analysts' price targets for Akebia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the following people:
  • Mr. John P. Butler MBA, CEO, Pres & Director (Age 57, Pay $1.02M)
  • Mr. Michel Dahan, Sr. VP & COO (Age 42, Pay $567.57k)
  • Ms. Nicole R. Hadas, Sr. VP, Chief Legal Officer & Sec. (Age 48, Pay $497.37k)
  • Mr. Jason A. Amello, Exec. Officer (Age 53, Pay $578.05k)
  • Mr. Dell Faulkingham, Sr. VP & Chief Commercial Officer (Age 48, Pay $615.74k)
  • Mr. David A. Spellman, Sr. VP, CFO & Treasurer (Age 44)
  • Ms. Kristen K. Sheppard J.D., Esq., VP of Investor Relations
  • Mr. Douglas Jermasek, VP of Marketing & Strategy
  • Ms. Tamara Dillon, Sr. VP of HR
  • Dr. Karen L. Tubridy, Sr. VP & Chief Devel. Officer (Age 59)

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics CEO John Butler on Glassdoor.com. John Butler has an approval rating of 97% among Akebia Therapeutics' employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Akebia Therapeutics' key competitors?

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.89%), Satter Management CO. L.P. (3.22%), Northern Trust Corp (1.21%), Dimensional Fund Advisors LP (1.21%), Rice Hall James & Associates LLC (1.07%) and Renaissance Technologies LLC (1.00%). Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke.
View institutional ownership trends for Akebia Therapeutics
.

Which major investors are selling Akebia Therapeutics stock?

AKBA stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Squarepoint Ops LLC, BlackRock Inc., SG Americas Securities LLC, Engineers Gate Manager LP, Alliancebernstein L.P., Virginia Retirement Systems ET AL, and Dynamic Technology Lab Private Ltd. Company insiders that have sold Akebia Therapeutics company stock in the last year include Dell Faulkingham, and Maxine Gowen.
View insider buying and selling activity for Akebia Therapeutics
or view top insider-selling stocks.

Which major investors are buying Akebia Therapeutics stock?

AKBA stock was purchased by a variety of institutional investors in the last quarter, including Satter Management CO. L.P., Renaissance Technologies LLC, Principal Financial Group Inc., Nisa Investment Advisors LLC, Russell Investments Group Ltd., Tudor Investment Corp Et Al, Bank of New York Mellon Corp, and Virtus ETF Advisers LLC. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke.
View insider buying and selling activity for Akebia Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $3.43.

How much money does Akebia Therapeutics make?

Akebia Therapeutics has a market capitalization of $495.77 million and generates $335 million in revenue each year. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Akebia Therapeutics have?

Akebia Therapeutics employs 358 workers across the globe.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is www.akebia.com.

Where are Akebia Therapeutics' headquarters?

Akebia Therapeutics is headquartered at 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.